{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024435","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.662774+00:00","generated_at":"2026-05-21T23:33:51.889010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026","bullets":["Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.","Cash and equivalents $125M at March 31, 2025; runway into 2027, extendable to 2028 by delaying new indications.","Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa on track; topline data expected in 2026.","Mike Heffernan appointed Chairman of the Board.","R&D expenses $9.1M (+$7M YoY) driven by LOTUS trial; G&A $5.5M (+$2.4M YoY) on stock compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024435","json":"https://secwatch.observer/filing/0001628280-25-024435.json","markdown":"https://secwatch.observer/filing/0001628280-25-024435.md","text":"https://secwatch.observer/filing/0001628280-25-024435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/0001628280-25-024435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/avtx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:33:51.889010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}